ArticleJTCVS open2026
Quadruple-valve replacement in patients with carcinoid heart disease: A 24-year experience.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Replacement of all 4 cardiac valves for carcinoid heart disease (CaHD) is rare. The purpose of this study was to evaluate the prevalence and outcomes after concomitant quadruple-valve replacement for CaHD. Methods: Between May 1999 and March 2022, 13 consecutive patients with CaHD underwent concomitant quadruple-valve replacement at our institution. We reviewed preoperative characteristics, intraoperative management, and operative outcomes using a prospectively maintained database. Descriptive statistics were used to assess patient characteristics and outcomes. Results: The median age was 61 years, and 9 patients (69.2%) were women. The majority (10/13) were in New York Heart Association (NYHA) class III or IV. All patients had moderate or severe valve regurgitation of all 4 valves. The median right ventricular systolic pressure was 54 mm Hg, and the left ventricular ejection fraction was 58%. All patients had liver metastasis, and 3 had bone metastasis. Operative mortality occurred in 2 patients (15.4%). The median length of stay was 9.0 days (interquartile range, 7.0-14.0 days). There was a nonsignificant improvement in NYHA class from an average of III preoperatively to II at 3 months postoperatively ( Conclusions: Quadruple-valve replacement in patients with carcinoid heart disease is associated with elevated operative mortality and limited life expectancy in most patients. Selection of these patients for surgery should be done carefully.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.